Rachel East has an MChem Integrated master’s in chemistry from Cardiff University. She is the resident analyst for Beacon TPD and frequently reviews key trends in TPD-specific therapeutic classes such as bivalent and monovalent degraders. She also analyses key properties such as targets, disease indication, drug discontinuations, and more. Rachel has published 10+ digests, landscapes, and infographics pertaining to the TPD drug development space and has experience presenting at key TPD conferences.